Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 16/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25239061 | 1.00 | HPGDS (0.51) | HPGDSCA1CA2CA9USP30 | |
| SCHEMBL103893 | 0.90 | CA1 (0.51) | CA1CA2CA9USP30 | |
| SCHEMBL26087371 | 0.85 | CA1 (0.47) | HPGDSCA1CA2CA9USP30 | |
| SCHEMBL26087369 | 0.85 | CA1 (0.47) | HPGDSCA1CA2CA9USP30 | |
| SCHEMBL4112154 | 0.85 | NPC1 (0.56) | CA1CA2CA9 | |
| SCHEMBL1962378 | 0.84 | NPC1 (0.58) | CA1CA2CA9 | |
| SCHEMBL5197638 | 0.83 | CA1 (0.47) | HPGDSCA1CA2CA9USP30 | |
| SCHEMBL1989732 | 0.81 | HDAC4 (0.48) | CA1CA2CA9USP30 | |
| SCHEMBL15739735 | 0.80 | CA1 (0.49) | CA1CA2CA9USP30 | |
| SCHEMBL17749191 | 0.78 | SMYD3 (0.50) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4450502-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2023113023-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | 佐藤製薬株式会社 | 2023-06-22 | — | — | WO | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | HPGDS 1/4885CA1 4273/4885CA2 1714/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | HPGDS 1/4885CA1 3544/4885CA2 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.